☰

Alex W. Tong - Publications

Affiliations: 
Baylor University, Waco, TX 
Area:
Cell Biology, Oncology
Tree Info Grants Similar researchers PubMed Report error

46 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Li B, Liu G, Hu H, Ding J, Zheng J, Tong A. Biomarkers Analysis for Heterogeneous Immune Responses of Quiescent CD8+cells -A Clue for Personalized Immunotherapy. Biomarkers Journal. 1. PMID 38085708  0.347
2012 Tong AW, Senzer N, Cerullo V, Templeton NS, Hemminki A, Nemunaitis J. Oncolytic viruses for induction of anti-tumor immunity. Current Pharmaceutical Biotechnology. 13: 1750-60. PMID 21740355 DOI: 10.2174/138920112800958913  0.4
2012 Shawler DL, Tong A, Liu L, Carrier E, Davis CS, Nemunaitis J, Fakhrai H. Abstract 5364: Correlation of immune responses and overall survival in a phase II study of belagenpumatucel-L, an allogeneic tumor cell vaccine, in non-small cell lung cancer (NSCLC) Cancer Research. 72: 5364-5364. DOI: 10.1158/1538-7445.Am2012-5364  0.306
2011 Phadke AP, Jay CM, Wang Z, Chen S, Liu S, Haddock C, Kumar P, Pappen BO, Rao DD, Templeton NS, Daniels EQ, Webb C, Monsma D, Scott S, Dylewski D, ... ... Tong AW, et al. In vivo safety and antitumor efficacy of bifunctional small hairpin RNAs specific for the human Stathmin 1 oncoprotein. Dna and Cell Biology. 30: 715-26. PMID 21612405 DOI: 10.1089/Dna.2011.1240  0.428
2011 Olivares J, Kumar P, Yu Y, Maples PB, Senzer N, Bedell C, Barve M, Tong A, Pappen BO, Kuhn J, Magee M, Wallraven G, Nemunaitis J. Phase I trial of TGF-beta 2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 183-92. PMID 21208907 DOI: 10.1158/1078-0432.Ccr-10-2195  0.348
2010 Rao DD, Maples PB, Senzer N, Kumar P, Wang Z, Pappen BO, Yu Y, Haddock C, Jay C, Phadke AP, Chen S, Kuhn J, Dylewski D, Scott S, Monsma D, ... ... Tong A, et al. Enhanced target gene knockdown by a bifunctional shRNA: a novel approach of RNA interference. Cancer Gene Therapy. 17: 780-91. PMID 20596090 DOI: 10.1038/Cgt.2010.35  0.325
2010 Nemunaitis J, Tong AW, Nemunaitis M, Senzer N, Phadke AP, Bedell C, Adams N, Zhang YA, Maples PB, Chen S, Pappen B, Burke J, Ichimaru D, Urata Y, Fujiwara T. A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 429-34. PMID 19935775 DOI: 10.1038/Mt.2009.262  0.343
2009 Phadke AP, Jay C, Chen SJ, Haddock C, Wang Z, Yu Y, Nemunaitis D, Nemunaitis G, Templeton NS, Senzer N, Maples PB, Tong AW, Nemunaitis J. Safety and in vivo expression of a GNE-transgene: a novel treatment approach for hereditary inclusion body myopathy-2. Gene Regulation and Systems Biology. 3: 89-101. PMID 19838336 DOI: 10.4137/Grsb.S2210  0.327
2009 Fernandes MS, Gomes EM, Butcher LD, Hernandez-Alcoceba R, Chang D, Kansopon J, Newman J, Stone MJ, Tong AW. Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4847-56. PMID 19622582 DOI: 10.1158/1078-0432.Ccr-09-0451  0.794
2009 Tong AW, Jay CM, Senzer N, Maples PB, Nemunaitis J. Systemic therapeutic gene delivery for cancer: Crafting Paris' arrow Current Gene Therapy. 9: 45-60. PMID 19275571 DOI: 10.2174/156652309787354630  0.389
2009 Gomes EM, Rodrigues MS, Phadke AP, Butcher LD, Starling C, Chen S, Chang D, Hernandez-Alcoceba R, Newman JT, Stone MJ, Tong AW. Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 1317-25. PMID 19228733 DOI: 10.1158/1078-0432.Ccr-08-1360  0.744
2009 Tong AW, Fulgham P, Jay C, Chen P, Khalil I, Liu S, Senzer N, Eklund AC, Han J, Nemunaitis J. MicroRNA profile analysis of human prostate cancers. Cancer Gene Therapy. 16: 206-16. PMID 18949015 DOI: 10.1038/Cgt.2008.77  0.554
2009 Fakhrai H, Tong A, Nemunaitis J, Shawler DL. Correlation of immune responses and survival in a phase II study of belagenpumatucel-L in non-small cell lung cancer Journal of Clinical Oncology. 27: 3013-3013. DOI: 10.1200/Jco.2009.27.15_Suppl.3013  0.303
2008 Fujiwara T, Tanaka N, Nemunaitis JJ, Senzer NN, Tong A, Ichimaru D, Shelby SM, Hashimoto Y, Kawamura H, Urata Y. Phase I trial of intratumoral administration of OBP-301, a novel telomerase-specific oncolytic virus, in patients with advanced solid cancer: Evaluation of biodistribution and immune response Journal of Clinical Oncology. 26: 3572-3572. DOI: 10.1200/Jco.2008.26.15_Suppl.3572  0.419
2008 Shelby SM, Ichimaru D, Kawamura H, Nagai K, Tong A, Nemunaitis JJ, Senzer NN, Fujiwara T, Urata Y. Safety, early efficacy, and demographic data from a phase I study of a replication selective adenovirus in patients with solid tumors Journal of Clinical Oncology. 26: 14526-14526. DOI: 10.1200/Jco.2008.26.15_Suppl.14526  0.354
2007 Jay C, Nemunaitis J, Chen P, Fulgham P, Tong AW. miRNA profiling for diagnosis and prognosis of human cancer. Dna and Cell Biology. 26: 293-300. PMID 17504025 DOI: 10.1089/Dna.2006.0554  0.561
2006 Zhang YA, Nemunaitis J, Samuel SK, Chen P, Shen Y, Tong AW. Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA. Cancer Research. 66: 9736-43. PMID 17018633 DOI: 10.1158/0008-5472.Can-06-1617  0.73
2006 Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, Tong A, Kumar P, Pappen B, Hamilton C, DeVol E, Maples PB, Liu L, Chamberlin T, Shawler DL, et al. Phase II Study of Belagenpumatucel-L, a Transforming Growth Factor Beta-2 Antisense Gene-Modified Allogeneic Tumor Cell Vaccine in Non–Small-Cell Lung Cancer Journal of Clinical Oncology. 24: 4721-4730. PMID 16966690 DOI: 10.1200/Jco.2005.05.5335  0.369
2006 Tong AW. Small RNAs and non-small cell lung cancer. Current Molecular Medicine. 6: 339-49. PMID 16712479 DOI: 10.2174/156652406776894554  0.443
2006 Nemunaitis JJ, Dillman RO, Schwarzenberger P, Senzer N, Tong A, Devol E, Chamberlin T, Shawler D, Fakhrai H. Phase II study of a TGF-{beta}2 antisense gene modified allogeneic tumor cell vaccine (Lucanix) in advanced NSCLC Journal of Clinical Oncology. 24: 7018-7018. DOI: 10.1200/Jco.2006.24.18_Suppl.7018  0.367
2006 Rodrigues MS, Gomes EM, Hernandez R, Chang J, Kansopon J, Newman J, Stone MJ, Tong AW. Growth Inhibition of Human Multiple Myeloma Cells by a CD40 Ligand (CD40L, CD154) Transgene - Oncolytic Virus Construct. Blood. 108: 3427-3427. DOI: 10.1182/Blood.V108.11.3427.3427  0.722
2006 Edelman G, Senzer N, Nemunaitis M, Cunningham C, Sovern P, Tong A, Nemunaitis J. 378. Phase I Trial of Intravenous Infusion of Onyx 015 and Enbrel in Solid Tumor Patients Molecular Therapy. 13. DOI: 10.1016/J.Ymthe.2006.08.438  0.373
2006 Tong AW, Zhang Y, Samuel S, Chen P, Shen Y, Nemunaitis J. 311. Target-Specific Knockdown and Enhanced Anti-Tumor Outcome by an Oncolytic Virus- Delivered Small Interfering RNA (siRNA) Molecular Therapy. 13. DOI: 10.1016/J.Ymthe.2006.08.366  0.754
2006 Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, Tong A, Kumar P, Pappen B, Hamilton C, DeVol E, Maples PB, Liu L, Chamberlin T, Shawler DL, et al. 1104. Phase II Study of Lucanix™ a Transforming Growth Factor β2 (TGF-β2) Antisense Gene Modified Allogeneic Tumor Cell Vaccine in Non Small Cell Lung Cancer (NSCLC) Molecular Therapy. 13. DOI: 10.1016/J.Ymthe.2006.08.1209  0.353
2005 Tong AW, Zhang YA, Nemunaitis J. Small interfering RNA for experimental cancer therapy. Current Opinion in Molecular Therapeutics. 7: 114-24. PMID 15844618  0.341
2005 Konduri K, Sahota SS, Babbage G, Tong AW, Kumar P, Newman JT, Stone MJ. Immunoglobulin M myeloma: evaluation of molecular features and cytokine expression. Clinical Lymphoma. 5: 285-9. PMID 15794867 DOI: 10.3816/Clm.2005.N.018  0.362
2005 Tong AW, Nemunaitis J, Su D, Zhang Y, Cunningham C, Senzer N, Netto G, Rich D, Mhashilkar A, Parker K, Coffee K, Ramesh R, Ekmekcioglu S, Grimm EA, van Wart Hood J, et al. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Molecular Therapy : the Journal of the American Society of Gene Therapy. 11: 160-72. PMID 15585417 DOI: 10.1016/J.Ymthe.2004.09.021  0.455
2005 Cunningham CC, Chada S, Merritt JA, Tong A, Senzer N, Zhang Y, Mhashilkar A, Parker K, Vukelja S, Richards D, Hood J, Coffee K, Nemunaitis J. Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study. Molecular Therapy : the Journal of the American Society of Gene Therapy. 11: 149-59. PMID 15585416 DOI: 10.1016/J.Ymthe.2004.09.019  0.396
2005 Tong AW. Oncolytic viral therapy for human cancer: Challenges revisited Drug Development Research. 66: 260-277. DOI: 10.1002/Ddr.20058  0.435
2004 Cunningham CC, Chada S, Merritt J, Tong A, Senzer N, Zhang Y, Mhashilkar A, Parker K, Vukelja S, Richards D, Hood J, Coffee K, Nemunaitis JJ. 1009. A Phase I Study of the Clinical and Local Biological Effects of Intratumoral Injection of mda-7 (INGN 241) in Patients with Advanced Carcinoma Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.947  0.4
2003 Nemunaitis J, Cunningham C, Tong A, Post L, Netto G, Paulson AS, Rich D, Blackburn A, Sands B, Gibson B, Randlev B, Freeman S. Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Therapy. 10: 341-52. PMID 12719704 DOI: 10.1038/Sj.Cgt.7700585  0.316
2003 Tong AW, Stone MJ. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Therapy. 10: 1-13. PMID 12489023 DOI: 10.1038/Sj.Cgt.7700527  0.57
2001 Tong AW, Zhang Y, Cunningham C, Maples P, Nemunaitis J. Potential clinical application of antioncogene ribozymes for human lung cancer. Clinical Lung Cancer. 2: 220-226. PMID 14700482 DOI: 10.3816/Clc.2001.N.007  0.43
2001 Nemunaitis J, Cunningham C, Buchanan A, Blackburn A, Edelman G, Maples P, Netto G, Tong A, Randlev B, Olson S, Kirn D. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Therapy. 8: 746-59. PMID 11420638 DOI: 10.1038/Sj.Gt.3301424  0.336
2001 Tong AW, Papayoti MH, Netto G, Armstrong DT, Ordonez G, Lawson JM, Stone MJ. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 7: 691-703. PMID 11297266  0.688
2000 Zhang Y, Nemunaitis J, Tong AW. Anti-K- ras 1 Ribozyme Adenoviral Vector for Gene Therapy of Non-Small Cell Lung Cancer Methods in Molecular Medicine. 35: 261-271. PMID 21390810 DOI: 10.1385/1-59259-086-1:261  0.377
2000 Tong AW, Seamour B, Lawson JM, Ordonez G, Vukelja S, Hyman W, Richards D, Stein L, Maples PB, Nemunaitis J. Cellular immune profile of patients with advanced cancer before and after taxane treatment. American Journal of Clinical Oncology. 23: 463-72. PMID 11039505 DOI: 10.1097/00000421-200010000-00007  0.315
2000 Zhang Y, Nemunaitis J, Tong AW. Generation of a ribozyme-adenoviral vector against K-ras mutant human lung cancer cells. Molecular Biotechnology. 15: 39-49. PMID 10911621 DOI: 10.1385/Mb:15:1:39  0.393
2000 Tong AW, Seamour B, Chen J, Su D, Ordonez G, Frase L, Netto G, Stone MJ. CD40 ligand-induced apoptosis is Fas-independent in human multiple myeloma cells. Leukemia & Lymphoma. 36: 543-58. PMID 10784400 DOI: 10.3109/10428190009148403  0.537
2000 Nemunaitis J, Cox J, Hays S, Meyer W, Kebart R, Ognoskie N, Courtney A, Yu Y, Rasmussen H, Tong A. Prognostic role of K-ras in patients with progressive colon cancer who received treatment with Marimastat (BB2516). Cancer Investigation. 18: 185-90. PMID 10754986 DOI: 10.3109/07357900009031822  0.329
1998 Singh A, Tong A, Ognoskie N, Meyer W, Nemunaitis J. Improved survival in patients with advanced colorectal carcinoma failing 5-fluorouracil who received irinotecan hydrochloride and have high intratumor C-fos expression. American Journal of Clinical Oncology. 21: 466-469. PMID 9781601 DOI: 10.1097/00000421-199810000-00009  0.315
1998 Nemunaitis J, Klemow S, Tong A, Courtney A, Johnston W, Mack M, Taylor W, Solano M, Stone M, Mallams J, Mues G. Prognostic value of K-ras mutations, ras oncoprotein, and c-erb B-2 oncoprotein expression in adenocarcinoma of the lung. American Journal of Clinical Oncology. 21: 155-160. PMID 9537203 DOI: 10.1097/00000421-199804000-00013  0.325
1996 Tong AW, Stone MJ. Cd40 And The Effect Of Anti-Cd40-Binding On Human Multiple Myeloma Clonogenicity Leukemia & Lymphoma. 21: 1-8. PMID 8907262 DOI: 10.3109/10428199609067572  0.501
1994 Tong AW, Zhang B, Mues G, Solano M, Hanson T, Stone MJ. Anti-CD40 antibody binding modulates human multiple myeloma clonogenicity in vitro. Blood. 84: 3026-3033. DOI: 10.1182/Blood.V84.9.3026.Bloodjournal8493026  0.47
1987 Yoshihara PH, Thieme T, Finke P, Barney C, Tong A, Burger DR. Characterization of a T-cell determinant defined by a monoclonal antibody (TH5.2) which is involved in the interleukin-2-producing and proliferative capabilities of T cells Cellular Immunology. 108: 10-27. PMID 3111721 DOI: 10.1016/0008-8749(87)90189-4  0.31
1986 Tong AW, Lee JC, Stone MJ. Discrimination of Human Small Cell and Non-Small Cell Lung Tumors by a Panel of Monoclonal Antibodies Journal of the National Cancer Institute. 77: 1023-1033. DOI: 10.1093/Jnci/77.5.1023  0.354
Show low-probability matches.